Industry News

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 
  • Cipla to acquire Inzpera Healthsciences, strengthens focus on Paediatric and Wellness Segment
    5 November 2025

    Cipla to acquire Inzpera Healthsciences, strengthens focus on Paediatric and Wellness Segment

    Pharmaceutical major Cipla Limited has announced the signing of definitive agreements to acquire 100% equity stake in Inzpera Healthsciences Limited, a company engaged in developing and marketing differentiated paediatric and wellness products. The announcement was made through a corporate filing with the Bombay Stock Exchange
  • 4 November 2025
    Zydus receives tentative nod from USFDA for Budesonide capsules
    Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) for Budesonide delayed-release capsules, 4 mg (USRLD: Tarpeyo Capsules, 4 mg).
  • 3 November 2025
    Pfizer Sues Metsera and Novo Nordisk over alleged breach of merger deal
    Pfizer Inc. announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit includes claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metseras alleged breach of its obligations under the merger agreement between Pfizer and Metsera.
  • 29 October 2025
    Teva reaches USD 35 million settlement in QVAR antitrust case
    Teva Pharmaceuticals USA, Inc., and affiliated companies have agreed to pay USD 35 million to resolve a class action lawsuit alleging that the drugmaker delayed generic competition for its asthma inhaler, QVAR
  • 28 October 2025
    Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival
    Merck known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with WELIREG
  • 28 October 2025
    Lupin pharma inaugurates new facility in New Jersey, USA
    Global pharmaceutical leader, Lupin Limited (Lupin), commemorated the inauguration of its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater, New Jersey. The new location expands Lupin’s presence in the state, which already includes manufacturing and research facilities in Somerset.
  • 27 October 2025
    Dr Reddy’s to Launch Generic Version of Wegovy in 87 Countries Next Year
    Dr Reddys Laboratories Ltd, one of Indias leading pharmaceutical companies, plans to launch a lower-cost generic version of Novo Nordisks blockbuster weight-loss drug Wegovy across 87 countries next year, according to the company’s Chief Executive Officer, Erez Israeli.
  • 27 October 2025
    Blenrep approved by USFDA for use in treatment of relapsed/refractory multiple myeloma
    GSK plc announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory (IMID) agent.
  • 26 October 2025
    Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline
    Avidity is committed to delivering a new class of pioneering RNA therapeutics called Antibody Oligonucleotide Conjugates for serious, genetic neuromuscular diseases. The proposed acquisition will bring Aviditys late-stage neuroscience programs into Novartis and provide Novartis access to a differentiated RNA-targeting delivery platform.
  • 23 October 2025
    Biocon Biologics receives approval of Psoriasis biosmilar in Canada

    Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced that Health Canada has granted a Notice of Compliance (NOC) for Yesintek™ (ustekinumab injection) and Yesintek™ I.V., a biosimilar to Stelara® (ustekinumab injection) and Stelara® I.V. (ustekinumab for injection, solution for intravenous infusion). The approval was granted on October 17, paving the way for Canadian commercial availability in mid-October.

Subscribe to Industry News